These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29807823)

  • 61. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).
    Apostolidis A; Averbeck MA; Sahai A; Rahnama'i MS; Anding R; Robinson D; Gravas S; Dmochowski R
    Neurourol Urodyn; 2017 Apr; 36(4):882-893. PubMed ID: 28444708
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Management of overactive bladder in women].
    Peyronnet B; Rigole H; Damphousse M; Manunta A
    Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients.
    Syan R; Zhang CA; Enemchukwu EA
    Urology; 2020 Aug; 142():81-86. PubMed ID: 32439551
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con.
    Bales GT
    J Urol; 2017 Sep; 198(3):500-501. PubMed ID: 28751016
    [No Abstract]   [Full Text] [Related]  

  • 68. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Pro.
    Kraus SR
    J Urol; 2017 Sep; 198(3):501-502. PubMed ID: 28751015
    [No Abstract]   [Full Text] [Related]  

  • 69. [Overactive bladder-which treatment when?].
    Pannek J
    Urologe A; 2017 Dec; 56(12):1532-1538. PubMed ID: 29043374
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
    Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
    World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tibial nerve stimulation in the treatment of overactive bladder syndrome: technical features of latest applications.
    Te Dorsthorst M; van Balken M; Heesakkers J
    Curr Opin Urol; 2020 Jul; 30(4):513-518. PubMed ID: 32452995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Update on Overactive Bladder Therapeutic Options.
    Babin CP; Catalano NT; Yancey DM; Pearl NZ; Koonce EM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Am J Ther; 2024 Jul-Aug 01; 31(4):e410-e419. PubMed ID: 37171410
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.
    Leroux PA; Brassart E; Lebdai S; Azzouzi AR; Bigot P; Carrouget J
    World J Urol; 2018 Sep; 36(9):1455-1460. PubMed ID: 29633085
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.
    Su X; Nickles A; Nelson DE
    BMC Urol; 2015 Jun; 15():50. PubMed ID: 26055982
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry.
    Jericevic D; Shapiro K; Bowman M; Vélez CA; Mbassa R; Fang R; Van Kuiken M; Brucker BM
    Urol Pract; 2024 Mar; 11(2):394-401. PubMed ID: 38226920
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
    Mohee A; Khan A; Harris N; Eardley I
    BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC; Liao CH; Chung SD
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.